Published Paper Details:

Oral drug delivery remains the most preferred route for drug administration due to its convenience, cost-effectiveness, and high patient compliance. However, a major challenge in oral drug delivery is the poor aqueous solubility and limited bioavailability of many newly developed drugs. Nearly 40-60% of new chemical entities (NCEs) belong to Biopharmaceutical Classification System (BCS) Class II and IV, characterized by low solubility and/or permeability. Poor solubility leads to erratic absorption, delayed onset of action, and variable therapeutic outcomes. Conventional oral formulations such as tablets and capsules often fail to achieve adequate systemic exposure for lipophilic drugs, as dissolution in the gastrointestinal (GI) fluids becomes the rate-limiting step. In response to these challenges, lipid-based formulations (LBFs) have emerged as promising alternatives, offering improved solubilization and lymphatic transport.